News | Brachytherapy Systems | January 04, 2019

Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer

Patient-reported outcomes show smaller late toxicity profile for brachytherapy with similar progression-free survival to brachytherapy plus external beam therapy

Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer

January 4, 2018 — Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity profile for external beam radiotherapy and brachytherapy (EBT+ B) versus transperineal interstitial permanent brachytherapy (B) alone in men with intermediate-risk prostate cancer. The results from the NRG Oncology trial RTOG 0232, presented at the 2018 American Society for Radiation Oncology (ASTRO) annual meeting, did show similarities in progression-free survival.

NRG-RTOG 0232 evaluated the differences between progression-free survival and patient-reported outcomes on two separate treatment arms. The first arm was treated with combined partial pelvis EBT+B, whereas the second was treated with B alone. Men with prostate carcinoma were randomly assigned to receive treatment on one of the two arms. Researchers measured changes from baseline to 4 and 24 months using expanded prostate index composite (EPIC) and assessed three prostate cancer-specific PRO domains that included bowel, urinary and sexual.

“Although progression-free survival was similar on both treatment arms, the addition of external beam therapy yielded a higher percentage of clinician-reported late grade 3 or greater toxicities. The patient-reported data confirms that brachytherapy alone is the superior treatment for this for men with intermediate risk prostate cancer, with less patient-reported side effects. Brachytherapy alone would also be the most cost efficient treatment option for patients,” stated Deborah W. Bruner, RN, Ph.D., FANN, the abstract’s lead author and the Emory University Senior Vice President for Research.

At 24 months following their treatment, researchers found that the men on the EBT + B arm reported poorer urinary, bowel and sexual PROs and much greater toxicities than the B alone arm. Late grade 3 or greater clinical reported toxicities were 13 percent for the EBT+B arm and 7 percent for the B alone arm. Late grade 3 or greater bladder/genitourinary toxicity, the major symptom of concern, was underreported by clinician-report compared to patient-report. Clinicians reported late grade 3 or greater bladder/genitourinary toxicities of 8 percent for the EBT+B arm and 3 percent for the B alone arm compared to patient reports of 34 percent bladder/genitourinary toxicities for the EBT+B arm and 23 percent for the B alone arm. This further demonstrated the critical role patient-reported outcomes play in assessing treatment efficacy and clinically relevant symptoms.

For more information: www.astro.org

Reference

Bruner D.W., Moughan J., Prestidge B.R., et al. Patient Reported Outcomes of NRG Oncology/RTOG 0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone in Intermediate Risk Prostate Cancer. Abstract presented at the annual meeting of the American Society for Radiation Oncology (ASTRO).

Related Content

Heidelberg University Hospital Treats First Patient Using Carbon Ion Therapy With RayStation
News | Treatment Planning | August 23, 2019
Heidelberg University Hospital, Germany, has started using the RayStation treatment planning system for carbon ion...
Surging Demand for Image-guided, Stereotactic Radiation Therapy Driving Fiducial Marker Growth
News | Radiation Therapy | August 22, 2019
As fiducial markers gain traction in parallel to rising incidences of various cancer affecting lung, prostate, abdomen...
Vaping Impairs Vascular Function

Image courtesy of the American Heart Association

News | Magnetic Resonance Imaging (MRI) | August 21, 2019
Inhaling a vaporized liquid solution through an e-cigarette, otherwise known as vaping, immediately impacts vascular...
Videos | Treatment Planning | August 21, 2019
This is an example of the Mirada DLCExpert deep learning software that automatically identifies organs, segments and
First Cancer Patient Treated With Accuray Radixact System With Synchrony Motion Tracking
News | Image Guided Radiation Therapy (IGRT) | August 21, 2019
Physicians at the Froedtert & the Medical College of Wisconsin (MCW) Clinical Cancer Center in Milwaukee have...
Videos | Patient Positioning Radiation Therapy | August 21, 2019
This is a quick demonstration of the Varian Identify image-guided patient positioning system at the...
Videos | Treatment Planning | August 21, 2019
This is a lung cancer tumor radiotherapy...
Videos | Computed Tomography (CT) | August 21, 2019
This is a quick walk around of a mobile 32-slice...
Improved Imaging Technique Could Increase Chances of Prostate Cancer Survival
News | Prostate Cancer | August 20, 2019
According to the American Cancer Society, approximately one in nine men will be diagnosed with prostate cancer in their...